Kronos Bio Presents Preliminary Data From Phase 1 Dose Escalation Portion Of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC
Portfolio Pulse from Benzinga Newsdesk
Kronos Bio, Inc. (NASDAQ:KRON) has announced positive preliminary data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 clinical trial of KB-0742 at the AACR-NCI-EORTC International Conference. KB-0742 is being developed to treat transcriptionally addicted solid tumors. The preliminary analysis included 28 patients who received doses from 10 mg up to 60 mg. KB-0742 demonstrated on-mechanism single agent anti-tumor activity and exhibited a manageable safety profile. The maximum tolerated dose has not yet been identified, and dosing of patients at the 80 mg dose level is underway.
October 13, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kronos Bio's positive preliminary data from the Phase 1/2 clinical trial of KB-0742 could potentially boost investor confidence and the company's stock price in the short term.
Positive clinical trial results often lead to increased investor confidence as they indicate progress in the company's drug development pipeline. This can lead to increased demand for the company's stock, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100